In vivo activation of peroxisome proliferator-activated receptor-δ protects the heart from ischemia/reperfusion injury in Zucker fatty rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 2, 2008, Pages 466-474

  Yue, Tian Li ^a   Nerurkar, Sandhya S ^a   Bao, Weike ^a   Jucker, Beat M ^a   Sarov Blat, Lea ^a   Steplewski, Klaudia ^a   Ohlstein, Eliot H ^a   Willette, Robert N ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; CASPASE 3; FATTY ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BAX; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; TROPONIN I; CARDIOTONIC AGENT; CYTOKINE; KETONE; MESSENGER RNA; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME ACTIVITY; FATTY ACID OXIDATION; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; UPREGULATION; ZUCKER RAT; ANIMAL; BLOOD; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HEART; METABOLIC SYNDROME X; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; FATTY ACIDS; HEART; KETONES; MALE; METABOLIC SYNDROME X; MYOCARDIAL REPERFUSION INJURY; PPAR DELTA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, ZUCKER; RNA, MESSENGER; THIAZOLES; TROPONIN I;

EID: 42449113843     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.135327     Document Type: Article

References (41)

1. Barish GD, Narkar VA, and Evans RM (2006) PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest 116:590-597.
2. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, et al. (2004) (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10:1245-1250.
3. Crow MT, Mani K, Nam YJ, and Kitsis RN (2004) The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 95:957-970.
4. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, and Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
5. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, and Desvergne B (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142:4195-4202.
6. Frangogiannis NG, Smith CW, and Entman ML (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53:31-47.
7. Gilde AJ, van der Lee KAJM, Willemsen PHM, Chinetti G, van der Leij GJ, van der Vusse GJ, Staels B, and Bilsen MV (2003) Peroxisome proliferator- activated receptor-α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92:518-524.
8. Glass CK (2006) Going nuclear in metabolic and cardiovascular disease. J Clin Invest 116:556-560.
9. Hochhauser E, Kivity S, Dffen D, Maulik N, Otani H, Barthum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, et al. (2003) Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol 284:H2351-H2359.
10. Huang J, Nakamura K, Ito Y, Uzuka T, Morikawa M, Iría S, Tomihara K, Tanaka T, Masuta Y, Ishii K, et al. (2005) Bcl-xL gene transfer inhibits Bax translocation and prolongs cardiac cold preservation time in rats. Circulation 112:76-83.
11. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
12. Jordan JE, Simandle SA, Tulbert CD, Busija DW, and Miller AW (2003) Fructose-fed rats are protected against ischemia/reperfusion injury. J Pharmacol Exp Ther 307:1007-1011.
13. Jucker BM, Rennigs AJ, Cline GW, Petersen KF, and Shulman GI (1997) In vivo NMR investigation of intramuscular glucose metabolism in conscious rats. Am J Physiol Endocrinol Metab273:E139-E148.
14. Kirito K, Watanabe T, Sawada K-I, Endo H, Ozqwa K, and Komatsu N (2002) Thrombopoietin regulates Bcl-xL gene expression through stat5 and phosphatidylinositol 3-kinase activation pathways. J Biol Chem 277:8329-8337.
15. Kostadinova R, Wahli W, and Michalik L (2005) PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 12:2995-3009.
16. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, et al. (2005) Mitochondrial DNA mutation, oxidative stress, and apoptosis in mammalian aging. Science 309:481-484.
17. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, and Evans R (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 302:453-457.
18. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, et al. (2006) PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 103:3444-3449.
19. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, and Dzau VJ (2003) Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9:1195-1201.
20. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, and Rosenzweig A (2001) Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104:330-335.
21. Matsuura H, Adachi H, Smart RC, Xu X, Arata J, and Jetten AM (1999) Correlation between expression of peroxisome proliferators-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol Cell Endocrinol 147:85-92.
22. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD, Bello BD, Semigran MJ, Bielsa-Masdeu A, Dec W, et al. (1999) Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A 96:8144-8149.
23. Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegan DA, Sznaidman ML, Lambert MH, et al. (2001) A selective peroxisome proliferators-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98:5306-5311.
24. Opie LH, Tansey M, and Kennely BN (1977) Proposed metabolic vicious circles in patients with large myocardial infarcts and high plasma-free-fatty acid concentrations. Lancet 2:890-892.
25. Park TS, Yamashita H, Blaner WS, and Goldberg IJ (2007) Lipids in the heart: a source of fuel and a source of toxins. Curr Opin Lipidol 18:277-282.
26. Paulson DJ and Tahiliani AG (1992) Cardiovascular abnormalities associated with human and rodent obesity. Life Sci 51:1557-1569.
27. Pesant M, Sueur S, Dutartre P, Tallandier M, Grimaldi PA, Rochette L, and Connat JL (2006) Peroxisome proliferator-activated receptor δ activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 69:440-449.
28. Peters JM, Lee SST, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, and Gonzalez (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferators- activated receptor-δ. Mol Cell Biol 20:5119-5128.
29. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, and Vazquez-Carrera M (2005) Peroxisome proliferator-activated receptor-δ activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 65:832-841.
30. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, and Delhon A (2002) PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-kB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435:143-151.
31. Schaffer JE (2003) Lipotoxicity: when tissue overeat. Curr Opin Lipidol 14:281-287.
32. Sznaidman ML, Haffner CD, Maloney PR, Fivesh A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, et al. (2003) Novel selective small molecule agonists for peroxisome proliferators-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg Med Chem Lett 13:1517-1521.
33. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, et al. (2003) Activation of peroxisome proliferators-activated receptor-δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 100:15924-15929.
34. van der Veen JN, Kruit JK, Havinga R, Baller JFW, Chimini G, Lestavel S, Staels B, Groot PHE, Groen AK, and Kuipers F (2005) Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res 46:526-534.
35. Vikramadithyan RK, Hirata K, Yagyu H, Hu Y, Augustus A, Homma S, and Goldberg IJ (2005) Peroxisome proliferators-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther 313:586-593.
36. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, and Evans RM (2003) Peroxisome proliferator-activated receptor- activates fat metabolism to prevent obesity. Cell 113:159-170.
37. Yamamura T, Otani H, Nakao Y, Hattori R, Osako M, and Imamura H (2001) IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart. Am J Physiol Heart Circ Physiol 280:H1191-H1200.
38. Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, Youker KA, and Taegtmeyer H (2002) Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 51:2587-2595.
39. Yue TL, Bao W, Gu JL, Cui J, Ling T, Ma XL, Olstein EH, and Jucker BM (2005) Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion- induced myocardial injury. Diabetes 54:554-562.
40. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, et al. (2003) Activation of peroxisome proliferators-activated receptor-α protects the heart from ischemia/reperfusion injury. Circulation 108:2393-2399.
41. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, et al. (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 104:2588-2594.